Cannabinoid-based pharmaceuticals company Teewinot Life Sciencess employs its patent-protected CANNSYNTHESIS® technology to biosynthesize cannabinoids for the large-scale manufacture of pharmaceutically pure cannabinoids. An article discussing the company’s technology reads: “Apart from THC and CBD, many of the 111 or so cannabinoids found in the cannabis plant are produced in minute quantities. Production by extraction is … Continue reading “QualityStocksNewsBreaks – Teewinot Life Sciences Produces Cannabinoids through Patent-protected CANNSYNTHESIS Technology”
Teewinot Life Sciences is on a mission to cut costs of cannabinoid production while approaching the process like a pharmaceutical company, not as a cannabis firm. An article discussing the company reads: “Teewinot Life Sciences is a Tampa, Florida-based global biopharmaceutical company focused on cannabinoid clinical development utilizing patented and proprietary synthetic biology and biocatalysis … Continue reading “QualityStocksNewsBreaks – Teewinot Life Sciences Lowers Production Cost of Clinical-Grade Cannabinoids with Proprietary Synthetic Biology Technology”
Producing cannabinoids through biosynthesis CANNSYNTHESIS® platform has capacity to scale up Revenues from out-licensing technology For the half a billion or so who suffer from one type or another of diabetes, biosynthesis offers a lifeline. For it is through biosynthesis that much of the world’s insulin is produced. Insulin regulates the metamorphosis of fats and … Continue reading “Teewinot Life Sciences Corporation is Producing Cannabinoids without Touching the Plant”
Company’s IP portfolio, including proprietary technology and biosynthetic methods, features seven U.S. patents and patent filings in numerous other key countries around the world Eliminating the high costs of cultivating plants, Teewinot Life Sciences Corporation delivers pure, consistent pharmaceutical-grade cannabinoids Company’s goal is to cut costs and approach cannabinoid production like a pharmaceutical company, not … Continue reading “Teewinot Life Sciences’ Patented Biosynthetic Tech Cuts Costs and Produces Clinical-Grade Cannabinoids”
Cannabinoid-based pharmaceuticals company Teewinot Life Sciences, along with its wholly-owned Irish subsidiary, Teewinot Technologies, Ltd., this morning announced the grant of U.S. Patent No. 9,879,292. The newly granted patent covers biosynthetic production of cannabinoids and cannabinoid analogs. “We are happy to announce the continued expansion of our valuable patent portfolio. Our technology platform enables standardized … Continue reading “QualityStocksNewsBreaks – Teewinot Life Sciences Subsidiary Granted New Broad Claiming U.S. Patent”
Cannabinoid-based pharmaceuticals company Teewinot Life Sciences Corporation has created patent protected methods to produce exact cannabinoid molecules called CANNSYNTHESIS®. An article discussing the company reads: “To protect this invaluable asset, Teewinot has taken aggressive intellectual property protection actions and filed patent applications in key countries around the world. Teewinot has created an exceptional combination of … Continue reading “QualityStocksNewsBreaks – Teewinot Life Sciences Positioned as Major Player in the Manufacture, Delivery of Cannabinoids Products”
Global medicinal cannabinoid market to exceed $55 billion by 2025 Teewinot has created patent protected methods to produce exact cannabinoid molecules called CANNSYNTHESIS® Efficient cost-effective methods reduce production time and increase purity There is indisputable scientific evidence of the curative effects of cannabinoids, and specialty biopharmaceutical companies are positioning to capitalize on the explosive growth … Continue reading “Teewinot Life Sciences Corporation: At the Vanguard of Biopharmaceutical Cannabinoid Therapeutics”
Cannabinoid-based pharmaceuticals company Teewinot Life Sciences Corporation this morning announced that it has been granted U.S. Patent No. 9,861,609. Per the update, the newly-issued patent has broad claims to biosynthetic methods for the pharmaceutical manufacture of cannabinoids and cannabinoid analogs. “With the grant of the ‘609 patent, Teewinot has now secured six U.S. patents covering … Continue reading “QualityStocksNewsBreaks – Teewinot Life Sciences Corporation Awarded Broad US Patent”
Holds 6 U.S. patents covering biosynthesis of cannabinoids, including first U.S. issued patent to create water-soluble cannabinoids Aggressively seeking intellectual property patent protection in key countries worldwide Able to manufacture kilogram quantities of 18 naturally occurring cannabinoids through biosynthetic processes Canadian subsidiary holds controlled substances license from Health Canada Teewinot Life Sciences is an international … Continue reading “Teewinot Life Sciences is “One to Watch””
AnalytixInsight Inc. (TSX.V: ALY) (OTCQB:ATIXF) ChineseInvestors.com (CIIX) DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) EVIO, Inc. (EVIO) First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF) Global Payout, Inc. (GOHE) Greenkraft, Inc. (GKIT) InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Net Element, Inc. … Continue reading “QualityStocks Prime Client Partners”
